Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate:An institutional experience

被引:0
|
作者
Almahari, Sayed Ali [1 ]
Harb, Zainab [1 ]
Alshaikh, Safa [1 ]
机构
[1] Salmaniya Med Complex, Dept Pathol, Manama, Bahrain
关键词
Atypia of undetermined significance; Bethesda system; follicular lesion of undetermined significance; FINE-NEEDLE-ASPIRATION; INCREASING INCIDENCE; UNDETERMINED SIGNIFICANCE; DIAGNOSTIC TERMINOLOGY; UNITED-STATES; CANCER; ATYPIA; MANAGEMENT; LESIONS; SYSTEM;
D O I
10.4103/cytojournal.cylojoumal_4_19
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background:Thyroid gland nodules are common and fine-needle aspiration (FNA) is the gold standard for screening those nodules.The Bethesda system for reporting thyroid cytolopathology standardized reporting thyroid nodules aspirations, but atypia of undetermined significance or follicular lesion of undetermined significance (Bethesda category III) was the most controversial category.The aim of our study is to review our institutional experience and analyze the clinical implications of making a diagnosis of AUS/FLUS (Bethesda category III). Methods: This is a retrospective study of an 889 thyroid FNAs from 825 patients in Salmaniya Medical Complex, during (January 2013-December 2017). Results:The most common cause for designating cases as AUS/FLUS (Bethesda category III) was the presence of features suggestive of papillary thyroid carcinoma, but not quite fulfilling the criteria for such diagnosis. Ninety-six cases were diagnosed asAUS/FLUS (10.7%),in which 26 (27%) patients underwent surgery without repeating the FNA,25 (26%) underwent a second FNA and 43 (44.7%) patients were followed up by ultrasound. On repeating the FNA, 1 (4%) was unsatisfactory, 13 (52%) were benign, 10 (40%) were AUS/FLUS, and only 1 (4%) was categorized as malignant.Thirty cases were surgically excised, in which 4 (13.3%) were diagnosed as follicular adenoma, 2 (6.6%) as Hurthle cell adenoma, 9 (30%) as multinodular goiter, 5 (16.6%) as multinodular goiter with Hashimoto thyroiditis, 1 (3.3%) as colloid nodule with Hashimoto thyroiditis, and 9 (30%) as papillary thyroid carcinoma.Among all the cases diagnosed initially as AUS/FLUS (Bethesda category III), 9 (9.3%) cases were diagnosed as papillary thyroid carcinoma. Conclusion: Diagnostically, we almost meet the international standards of designating cases with AUS/FLUS (Bethesda category III) and approximate the risk of malignancy. However, the clinical management's guidelines should be followed to decrease the risk of unnecessary surgeries and their complications.There is a statistically significant correlation between the age and gender with the final histopathology report, respectively.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)
    Ho, Allen S.
    Sarti, Evan E.
    Jain, Kunal S.
    Wang, Hangjun
    Nixon, Iain J.
    Shaha, Ashok R.
    Shah, Jatin P.
    Kraus, Dennis H.
    Ghossein, Ronald
    Fish, Stephanie A.
    Wong, Richard J.
    Lin, Oscar
    Morris, Luc G. T.
    [J]. THYROID, 2014, 24 (05) : 832 - 839
  • [2] Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
    Liu, Xiaoli
    Wang, Jingjing
    Du, Wei
    Dai, Liyuan
    Fang, Qigen
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [3] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS): Is There a Correct Answer?
    Heller, Keith S.
    [J]. THYROID, 2014, 24 (05) : 787 - 788
  • [4] Evaluation of thyroid nodules classified as Bethesda category III on FNAC
    Garg, Shiwani
    Naik, Leena P.
    Kothari, Kanchan S.
    Fernandes, Gwendolyn C.
    Agnihotri, Mona A.
    Gokhale, Jagruti C.
    [J]. JOURNAL OF CYTOLOGY, 2017, 34 (01) : 5 - 9
  • [5] Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III
    Iskandar, Mazen E.
    Bonomo, Giovanni
    Avadhani, Vaidehi
    Persky, Mark
    Lucido, David
    Wang, Beverly
    Marti, Jennifer L.
    [J]. SURGERY, 2015, 157 (03) : 510 - 517
  • [6] Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region
    Kasap, Zeliha Aydin
    Kurt, Burcin
    Ozsagir, Elif
    Ercin, Mustafa Emre
    Guner, Ali
    [J]. DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (04) : 200 - 210
  • [7] Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience
    Koseoglu, Derya
    Ozdemir Baser, Ozden
    Cetin, Zeynep
    [J]. DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (10) : 1110 - 1115
  • [8] Comments on "diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region"
    Goel, Archit
    Kapatia, Gargi
    Gupta, Shruti
    Gupta, Vikasdeep
    Sidana, Shivani
    [J]. DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (05) : 288 - 289
  • [9] Tumor Growth Rate Does Not Predict Malignancy in Surgically Resected Thyroid Nodules Classified as Bethesda Category III with Architectural Atypia
    Kim, Mijin
    Jeon, Min Ji
    Han, Minkyu
    Lee, Jeong Hyun
    Song, Dong Eun
    Baek, Jung Hwan
    Kim, Tae Yong
    Kim, Won Bae
    Shong, Young Kee
    Kim, Won Gu
    [J]. THYROID, 2019, 29 (02) : 216 - 221
  • [10] Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III
    Mileva, Magdalena
    Stoilovska, Bojana
    Jovanovska, Anamarija
    Ugrinska, Ana
    Petrushevska, Gordana
    Kostadinova-Kunovska, Slavica
    Miladinova, Daniela
    Majstorov, Venjamin
    [J]. RADIOLOGY AND ONCOLOGY, 2018, 52 (04) : 370 - 376